Loading...
Market
How will Roche's stock perform post-Poseida acquisition by January 2026?
2
Resolution / Starting Odds
Stock rises more than 10% • 25%
Stock rises 0-10% • 25%
Stock remains flat or declines 0-10% • 25%
Stock declines more than 10% • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
Increase by 0-20% • 25%
Decrease by more than 20% • 25%
Decrease by 0-20% • 25%
Increase by more than 20% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No significant change or decrease • 25%
Increase by 5-10% • 25%
Increase by more than 10% • 25%
Increase by less than 5% • 25%
Yes • 50%
No • 50%
Decrease > 10% • 25%
Increase > 10% • 25%
Increase ≤ 10% • 25%
Decrease ≤ 10% • 25%
